Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, announced the completion of a US$150 million fi...
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD ...
SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) announced that they have entered into an ...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Genera...
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...
- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, announced a strategic pa...
Proton therapy CBCT imaging solution across Proteus® Portfolio providing clarity and confidence in IGPT IBA (Ion Beam Applications S.A., EURON...
Dark Horse Consulting Group, a leading strategic and operational consulting enterprise in the field of biological therapy (hereinafter referred to as " DHC...
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of concept First-of-its-kind ...
Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially recei...
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positiv...
© 2026 Biopharma Boardroom. All Rights Reserved.
